Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Arjun Pandey(University of Ottawa), Subodh Verma(St. Michael's Hospital), Nikolaus Marx(RWTH Aachen University), Javed Butler(Jackson Memorial Hospital), Bertram Pitt(Bayer (Germany)), Francesco Cosentino(Linköping University), Ori D. Rotstein(St. Michael's Hospital), Ambarish Pandey(The University of Texas Southwestern Medical Center), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 71
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k